Home > Journals > Minerva Endocrinology > Past Issues > Minerva Endocrinologica 2020 December;45(4) > Minerva Endocrinologica 2020 December;45(4):376-80

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW   

Minerva Endocrinologica 2020 December;45(4):376-80

DOI: 10.23736/S0391-1977.20.03390-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Polycystic ovary syndrome, amenorrhea and the diagnostic role of anti-Müllerian hormone

Martina CAPUZZO 1, Valeria DONNO 1, Antonio LA MARCA 1, 2

1 Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Modena, Italy; 2 Clinica EUGIN, Modena, Italy



The differential diagnosis of anovulatory disorders is actually based on serum gonadotrophin and estradiol levels. However, several other markers have been proposed. The purpose of this review was to underline the role of anti-Müllerian hormone (AMH) as a possible marker in differential diagnosis of the anovulatory diseases and its use as a predictive marker of prognosis. In this article we discuss clinical and experimental evidences actually existing in literature and we suggest new potential clinical application of AMH.


KEY WORDS: Anti-Müllerian hormone; Polycystic ovary syndrome; Amenorrhea; Menopause, premature

top of page